Product Information
VENLAFAXINE HCL ER 150 MG CAP is a generic product labeled by Major Pharmaceuticals, priced at $0.1190 per EA under NDC 00904748961. Its NADAC has been published 32 times since Feb 25, 2026.
FDA first approved this application on Apr 14, 2011. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150 mg/1
Manufacturer
Major PharmaceuticalsNDC
00904748961
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
VENLAFAXINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA200834FDA Approved
4/14/2011
TE Code
AB
On Market Since
10/8/2025
Pharmacological Classes
Price Statistics
The NADAC for VENLAFAXINE HCL ER 150 MG CAP has been published 32 times since Feb 25, 2026, and over the history we have for it it has declined 3.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1190 per EA |
|---|---|
| All-time high | $0.1239 (Mar 11, 2026) |
| All-time low | $0.1152 (Jul 22, 2026) |
| 52-week high | $0.1239 |
| 52-week low | $0.1152 |
| Median price | $0.1193 |
| Average price | $0.1194 |
| Largest weekly change | +2.4% (Sep 23, 2026) |
| Weeks tracked | 32 |
| Tracking since | Feb 25, 2026 |
Generic Alternatives
The matcher finds 8 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Major Pharmaceuticals manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Venlafaxine Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin and Norepinephrine Reuptake Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VENLAFAXINE HCL ER 150 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for VENLAFAXINE HCL ER 150 MG CAP, manufactured by Major Pharmaceuticals, is $0.1190 per EA (NDC 00904748961), effective Sep 30, 2026.
How has the price of VENLAFAXINE HCL ER 150 MG CAP changed over time?
Over the history we have for it, the NADAC for VENLAFAXINE HCL ER 150 MG CAP has declined 3.9%. It has been tracked across 32 weekly CMS publications since Feb 25, 2026.
What are the highest and lowest recorded NADAC prices for VENLAFAXINE HCL ER 150 MG CAP?
Since Feb 25, 2026, the NADAC for VENLAFAXINE HCL ER 150 MG CAP has ranged from a low of $0.1152 (Jul 22, 2026) to a high of $0.1239 (Mar 11, 2026), with a median of $0.1193 per EA.
Are there cheaper alternatives to VENLAFAXINE HCL ER 150 MG CAP?
8 manufacturers publish a NADAC-priced product with the same active ingredient and strength as VENLAFAXINE HCL ER 150 MG CAP in a comparable dosage form, but none are currently priced below it.
Who manufactures VENLAFAXINE HCL ER 150 MG CAP?
VENLAFAXINE HCL ER 150 MG CAP (NDC 00904748961) is labeled by Major Pharmaceuticals, and CMS classifies it as a generic product.